Teva gets CRL for Huntington's candidate

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) received an FDA complete response letter for SD-809 deutetrabenazine to treat chorea associated with Huntington's

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE